Literature DB >> 23801512

Sufentanil in anaesthesiology and intensive therapy.

Dariusz Maciejewski1.   

Abstract

Sufentanil, a potent α-1 agonistic opioid, was synthesized in mid-1970s. It was introduced into clinical practice ten years later, gaining some popularity over the last twenty years. A piperidine derivative, sufentanil has been reported to be 6-10 times more potent than fentanyl, depending on the route of administration; it has been registered for intravenous, epidural and subarachnoid administration. Its reported off-label use has included intra-articular and intranasal administration; moreover, it has been applied as an adjunct in peripheral blocks. In the review, contemporary uses of sufentanil, together with detailed pharmacokinetics and pharmacodynamics are presented. The author concludes that the limited side effects of sufentanil, together with its attractive pharmacokinetic profile, should promote its wider use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23801512

Source DB:  PubMed          Journal:  Anaesthesiol Intensive Ther        ISSN: 1642-5758


  12 in total

1.  Effectiveness of Patient-Controlled Intravenous Analgesia (PCIA) with Sufentanil Background Infusion for Post-Cesarean Analgesia: A Randomized Controlled Trial.

Authors:  Zhongbiao Nie; Xianmei Cui; Ran Zhang; Zhihong Li; Bin Lu; Suxian Li; Tao Cao; Ping Zhuang
Journal:  J Pain Res       Date:  2022-05-06       Impact factor: 2.832

2.  Safety and efficacy of sufentanil combined with midazolam in bronchoscopy under conscious sedation: retrospective study of 11,158 cases.

Authors:  Yao Yao; Zhuquan Su; Yu Chen; Yongshun Ye; Liya Lu; Changhao Zhong; Xiaobo Chen; Chunli Tang; Shiyue Li
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

3.  An efficient, optimized synthesis of fentanyl and related analogs.

Authors:  Carlos A Valdez; Roald N Leif; Brian P Mayer
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

4.  Comparison of the Effects of Sufentanil and Fentanyl Intravenous Patient Controlled Analgesia after Lumbar Fusion.

Authors:  Do Keun Kim; Seung Hwan Yoon; Ji Yong Kim; Chang Hyun Oh; Jong Kwon Jung; Jin Kim
Journal:  J Korean Neurosurg Soc       Date:  2016-12-29

5.  Comparison of Sufentanil- and Fentanyl-based Intravenous Patient-controlled Analgesia on Postoperative Nausea and Vomiting after Laparoscopic Nephrectomy: A Prospective, Double-blind, Randomized-controlled Trial.

Authors:  Hye-Mi Lee; Hae Keum Kil; Bon Nyeo Koo; Min Sup Song; Jin Ha Park
Journal:  Int J Med Sci       Date:  2020-01-14       Impact factor: 3.738

6.  Recommended dose of sufentanil during induction of general anesthesia to avoid coughing and drastic hemodynamic fluctuations in patients undergoing surgery.

Authors:  Ping Chen; Ping Zeng; Yuan Gong; Xiang Long
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

7.  Associations of Fentanyl, Sufentanil, and Remifentanil With Length of Stay and Mortality Among Mechanically Ventilated Patients: A Registry-Based Cohort Study.

Authors:  Wen Wang; Qiao He; Mingqi Wang; Yan Kang; Peng Ji; Shichao Zhu; Rui Zhang; Kang Zou; Xin Sun
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

8.  Intrathecal Sufentanil Does Not Reduce Shivering During Neuraxial Anesthesia: A Meta-Analysis.

Authors:  Lin Shao Feng; Gao Hong; Zhao Yan; Liu Yan Qiu; Li An Liang
Journal:  Med Sci Monit       Date:  2016-01-25

9.  Dexmedetomidine-midazolam versus Sufentanil-midazolam for Awake Fiberoptic Nasotracheal Intubation: A Randomized Double-blind Study.

Authors:  Cheng-Wen Li; Yan-Dong Li; Hai-Tao Tian; Xian-Gang Kong; Kui Chen
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628

10.  Comparison of the Analgesic Effect of Sufentanil versus Fentanyl in Intravenous Patient-Controlled Analgesia after Total Laparoscopic Hysterectomy: A Randomized, Double-blind, Prospective Study.

Authors:  Seok Kyeong Oh; Il Ok Lee; Byung Gun Lim; Hyerim Jeong; Young Sung Kim; Sul Gi Ji; Jong Sun Park
Journal:  Int J Med Sci       Date:  2019-09-20       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.